Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $547.91, for a total value of $5,205,145.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,197,477.83. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Price Performance

Shares of UTHR opened at $549.47 on Thursday. The stock’s 50-day moving average is $567.74 and its two-hundred day moving average is $518.04. The stock has a market cap of $23.33 billion, a PE ratio of 20.28, a P/E/G ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.63 EPS. On average, research analysts anticipate that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent analyst reports. UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Royal Bank Of Canada cut their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Torren Management LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.